Abstract
Background. Renal functional outcome is unpredictable after revascularization of high-grade atherosclerotic renal artery stenosis (RAS). 'Hibernating' parenchyma describes acute parenchymal injury where renal dysfunction is potentially reversible with treatment of the stenosis. We analysed renal parenchymal volume (PV) and single-kidney glomerular filtration rate (SK-GFR) characteristics to identify kidneys with hibernating parenchyma and hence determine renal functional outcome after revascularization. Methods. Fifty patients with ≥50% RAS underwent baseline analyses: (i) PV using magnetic resonance imaging; (ii) radioisotopic SK-GFR. Twenty-one patients (27 kidneys) underwent renal revascularization and 29 medical therapy alone.
Results. Patients with revascularized kidneys manifesting high PV:SK-GFR showed improvement in global estimated GFR compared to conservatively managed counterparts at 6 months and 1 year (6 months: 6.2 ± 2.9 versus −3.7 ± 6.8, P = 0.038; 1 year: 3.5 ± 3.0 versus −5.1 ± 5.1 ml/min/1.73 m 2 , P = 0.021). Twelve revascularized patients (16 kidneys) underwent repeat SK-GFR 4 months post-revascularization. Six of 16 revascularized kidneys had high baseline PV: SK-GFR and showed improved SK-GFR compared to kidneys with low or normal PV:SK-GFR (6.3 ± 2.0 versus −0.9 ± 4.2 ml/min, P = 0.002). Conclusions. Our data suggest that, after revascularization, GFR improvement is likely if there is a disproportionately higher baseline PV:SK-GFR in the RAS kidney. Analysing these parameters can potentially identify these 'hibernat-
Introduction
Atherosclerotic renovascular disease (ARVD) is commonly associated with chronic and end-stage renal disease [1, 2] . Renal revascularization procedures are frequently used in the treatment of high-grade renal artery stenosis (RAS). However, variable results relating to renal functional outcomes have been published after these procedures [3] [4] [5] [6] ; the majority showing no change, and only a minority having renal functional improvement. This heterogeneity is thought to reflect the aetiological importance of pre-existing chronic parenchymal damage in the pathogenesis of renal dysfunction in ARVD rather than simply being due to the effects of the arterial stenosis itself [7, 8] . Kidneys showing functional improvement following revascularization are likely to reflect a subgroup whose renal dysfunction is truly caused by the haemodynamic effect of the stenosis. The term 'hibernating parenchyma' has been used to describe this subgroup of kidneys when irreversible parenchymal injury has yet to occur and where renal dysfunction is thought to be potentially reversible with treatment of the stenosis [9] . As renal revascularization procedures can be associated with complications, the major challenge remains to identify patients who are most likely to benefit.
Renal bipolar length is widely used as a clinical indicator of chronicity and indirectly to estimate severity of pre-existing parenchymal damage [10] . Progressive renal shrinkage occurs in kidneys supplied by significant RAS [11] , and often, bipolar length is used to determine whether renal revascularization should be performed. However, bipolar length is a poor predictor of parenchymal volume and renal function; this is emphasized by studies utilising magnetic resonance (MR) imaging [12] [13] [14] and computed tomography (CT) [15] to assess renal morphology. In kidneys with atherosclerotic RAS, parenchymal volume (PV) is the best morphological correlate of single-kidney glomerular filtration rate (SK-GFR) as opposed to bipolar length and cortical thickness when assessed with MR [13] . In a previous study, we identified a subgroup of kidneys supplied by a highgrade RAS with disproportionately higher PV to SK-GFR [13] . We hypothesize that the extent of chronic parenchymal disease in such kidneys will be less severe (i.e. 'hibernating') than in kidneys with a comparatively lower PV:SK-GFR, and hence more likely to manifest improved renal function after revascularization. We investigate the relationship between PV and SK-GFR, and renal functional outcome after revascularization of significant RAS.
Subjects and methods

Patient population
Patients diagnosed with significant (≥50%) RAS by previous imaging (intra-arterial, digital subtraction, CT or MR renal angiography) were approached to participate in this study. The patient population includes 35 from a previous published study that examined the relationship between MR volume and SK-GFR in ARVD [13] . Fifty-nine patients whose clinical screening had led to a diagnosis of ARVD consented to undergo baseline assessment of renal PV using MR and radioisotopic assessment of SK-GFR (isoSK-GFR) by a standard technique. Renal angiography identified 50 patients with at least a unilateral significant (≥50%) RAS that was suitable for revascularization. Twenty-one patients proceeded to renal revascularization (27 kidneys revascularized) and 29 patients remained on standard medical treatment. The isoSK-GFR was repeated at 4 months following the revascularization procedure. Baseline clinical data were recorded: age, gender, blood pressure, macrovascular disease (ischaemic heart disease, cerebrovascular disease and peripheral vascular disease), serum creatinine, 24-hour proteinuria, statin therapy, angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin-receptor blocker (ARB) use. Significant proteinuria was defined as >0.5 g/day.
Renal functional assessment Global estimated GFR. Follow-up serum creatinine was recorded at 6 months and 1 year. Estimated GFR (eGFR) was calculated using modification of diet in renal disease (MDRD) equation [ Tc-DMSA on scintigraphy. The isoSK-GFR was unadjusted for surface area for analysis with parenchymal volume. In patients who underwent renal revascularization, isoSK-GFR was also repeated at 4 months following the procedure in those who agreed. The daily variation in isoSK-GFR has been shown to be 8.8% [19] ; improvement in individual renal function was therefore defined as a >15% and also >1 ml/min (as some kidneys had very low baseline SK-GFR) increase of isoSK-GFR at 4 months post-revascularization compared to baseline.
The protocol had the approval of the Local Research Ethics Committee in accordance with the Declaration of Helsinki.
MR imaging. MR imaging was performed at 1.0T (Magnetom Expert; Siemens Medical Systems, Germany) in the first 39 patients recruited and at 3.0T (Achieva; Philips Medical Systems, Best, the Netherlands) for subsequent 20 patients. Following acquisition of scout images, a 3D imaging volume was acquired using a T1-weighted spoiled gradient echo acquisition in the oblique-coronal plane. The volume encompassed both kidneys and the descending aorta, and the data were obtained in a single breathhold. The following parameters were used for the 1.0T acquistion: repetition time (TR) = 5.4 ms, echo time (TE) = 2.2 ms, field of view (FOV) = 350 × 306 × 80 mm, flip angle = 20°, four signal averages, following interpolation in the Fourier domain matrix = 128 × 112 × 32). The following parameters were used for the 3.0T acquistion: TR = 4.0 ms, TE = 1.0 ms, FOV = 400 × 400 × 80 mm, flip angle = 14°, two signal averages, parallel acquisition using a sensitivity encoding (SENSE) factor = 2, following interpolation in the Fourier domain matrix = 256 × 256 × 40). Gadolinium was not used for acquisition of 3D volume data.
The renal arterial anatomy was graded: normal vessel, insignificant (<50%) RAS, significant (≥50%) RAS or complete occlusion (RAO). The renal arterial anatomies were confirmed by standard contrast-enhanced MR angiography. The kidney volumes were calculated from the 3D volume images using the voxel-count method applied to coronal MR images [12] .
Renal volume (millilitre) = ∑(parenchymal area × slice thickness) nth slice Two measurements of parenchymal volume were averaged for data analysis. Using Bland-Altman analysis, intra-observer variabilty for parenchymal volume mapping was tested with a mean difference of 1.1% and for inter-observer variability 4.1% comparable to others [12] .
PV:isoSK-GFR. For the purpose of PV:isoSK-GFR analysis, kidneys supplied by normal vessel or insignificant RAS were used as a reference.
It is hypothesized that ≥50% RAS kidneys with similar PV:SK-GFR characteristics to that of their normal or insignificant RAS counterparts are unlikely to show any improvement in GFR following renal revascularization; and conversely, ≥50% RAS kidneys that exhibit a higher PV: SK-GFR are more likely to show an improvement in GFR following revascularization and assume comparable PV:SK-GFR characteristics of normal vessel or insignificant RAS kidneys. The normal vessel or insignificant RAS kidneys were grouped according to their parenchymal volume. With renal damage and shrinkage, cortical loss occurs to a greater degree than that of the medulla [20] , and hence, the ratio of PV to SK-GFR does increase as the kidney decreases in size (Table 1) . A kidney supplied by a significant ≥50% RAS was considered to have a high PV:isoSK-GFR ratio when this exceeded the upper limit of the 95% confidence interval (CI) for normal vessel or insignificant RAS kidneys of a given volume group. Where there was bilateral significant RAS, the average renal parenchymal volume and isoSK-GFR was used to calculate the PV:isoSK-GFR.
Evaluation criteria and statistical analysis. Parametric data are presented as mean ± standard deviation. Differences in continuous variables between groups were compared by the use of analysis of variance and post hoc analysis using Bonferroni correction. Renal functional change was analysed in two ways: (i) whole patient analysis i.e. difference between baseline and follow-up global eGFR as estimated by the MDRD equation; and (ii) individual revascularized kidney analysis i.e. difference between baseline and follow-up isoSK-GFR where patients agreed to a repeat isoSK-GFR study. Logistic regression was used to calculate the odds ratio (OR) for renal functional deterioration in the conservatively managed group, and improvement in the revascularized group. Significance level was set at 5%. SPSS software version 11.5 was used.
Results
Of 21 patients who underwent renal angioplasty and stent insertion, 2 had revascularization of single kidneys, 13 unilateral and 6 bilateral (27 kidneys). Three had no renal functional follow-up data as a result of death or declined further participation. Twenty-nine patients were treated without revascularization therapy (i.e. conservatively).
The baseline patient characteristics between conservative and revascularization groups are shown in Table 2 . The revascularization group had a lower global eGFR [MDRD, not significant (NS)] and global radioisotopic GFR (isoGFR, P = 0.027) than the conservative group.
Analysis of renal functional change by global eGFR (MDRD)
Overall, changes in eGFR were similar in conservative and revascularized groups at 6 months and 1 year (Table 3) .
Patients treated conservatively who had kidneys with high PV:isoSK-GFR showed a greater eGFR deterioration compared with patients who had kidneys with low or normal PV:isoSK-GFR at 6 months (−3.7 ± 6.8 versus 1.3 ± 6.2 ml/min/1.73 m 2 , respectively, P = 0.064) and significantly at 1 year (−5.1 ± 5.1 versus 1.0 ± 5.0 ml/min/1.73 m 2 , respectively, P = 0.005) ( Table 4) . Overall improvements in eGFR were seen in the revascularized group with high PV:isoSK-GFR compared with those with low or normal PV:isoSK-GFR, at 6 months and 1 year (6 months: 6.2 ± 2.9 versus 0.3 ± 6.2 ml/min/1.73 m 2 , NS; 1 year: 3.5 ± 3.0 versus -2.1 ± 5.7 ml/min/1.73 m 2 , NS); these differences did not achieve statistical significance. However, when percentage change in eGFR was analysed in the revascularized group, there was a significant percentage improvement in those with high PV:isoSK-GFR kidneys compared with those with low or normal, at 6 months (27.5 ± 14.7% versus −1.1 ± 17.0%, P = 0.015) and 1 year (16.4 ± 13.5% versus −8.5 ± 17.3%, P = 0.033). Revascularized patients exhibiting kidneys with high PV:isoSK-GFR had significantly better renal functional outcome than those treated conservatively at 6 months (6.2 ± 2.9 versus -3.7 ± 6.8 ml/min/1.73 m 2 , respectively, P = 0.038) and at 1 year (3.5 ± 3.0 versus −5.1 ± 5.1 ml/min/1.73 m 2 , respectively, P = 0.021). These results are depicted in Figure 1 . Therapy with ACE-I or ARB did not affect the change in eGFR at 1 year between the conservative and revascularization groups, or between the high PV:isoSK-GFR and low or normal PV:isoSK-GFR groups.
Predictors of >15% deterioration in eGFR at 1 year in the conservative group are shown in Table 5 . Univariate analysis found two factors affecting outcome: >0.5 g/ day proteinuria and high PV:isoSK-GFR. More than 0.5 g/day of proteinuria was associated with a near 38-fold increased risk of renal functional decline at 1 year. A high PV:isoSK-GFR was also associated with a significant 7-fold increase risk of deterioration. Although not statistically significant, there were trends to suggest ACE-I or ARB, and statin therapy were associated with a protective effect (OR 0.4 and 0.5, respectively) against renal function decline.
Of the 18 revascularized patients with available followup data, three showed overall eGFR improvement, of which two had kidneys with high PV:isoSK-GFR. Of the 15 revascularized patients with low or normal PV:SK-GFR, only one had diabetes mellitus. Fourteen (93.3%) of the 15 who showed a deterioration or no change in eGFR at 1 year after revascularization had kidneys with low or normal PV:isoSK-GFR. For those patients who were revascularized, only kidneys with a high PV:SK-GFR predicted an improvement in renal function of >15% at 1 year (OR 28.0, 95% CI 1.2-648.8) ( Table 6 ).
Analysis of renal functional change according to isoSK-GFR
Twelve revascularized patients had isoSK-GFR measured at baseline and 4 months post-revascularization (Table 7) . Only one of these patients had a diagnosis of diabetes mellitus. Eight patients had bilateral ≥50% RAS, one had ≥50% RAS and RAO, and three unilateral ≥50% RAS and contralateral <50% RAS or normal vessel. Four underwent bilateral and eight unilateral renal angioplasty and stent insertion (16 revascularized kidneys). Seven (44%) revascularized kidneys showed improvement of >1 ml/min and >15% isoSK-GFR. Of the 16 revascularized kidneys, six had high PV: isoSK-GFR, and 10 low or normal PV:isoSK-GFR. Prerevascularization isoSK-GFR was significantly lower in those with high PV:isoSK-GFR than kidneys with low or normal PV:isoSK-GFR (9.9 ± 6.7 versus 19.6 ± 9.6 ml/min, respectively, P = 0.049). There were no significant differences in post-revascularization isoSK-GFR between the two groups of kidneys (16.2 ± 7.8 versus 18.7 ± 8.4 ml/min, respectively, NS). There was significant improvement in isoSK-GFR following revascularization in the high PV:isoSK-GFR kidneys compared to the low or normal PV:isoSK-GFR kidneys (6.3 ± 2.0 versus −0.9 ± 4.2 ml/min, respectively, P = 0.002). Of the seven kidneys showing >15% improvement in isoSK-GFR post-revascularization, six (85.7%) had high PV:isoSK-GFR at baseline. The remaining nine kidneys all had a low or normal baseline PV:isoSK-GFR and did not show significant improvement in isoSK-GFR post-revascularization.
Baseline PV:isoSK-GFR characteristics are compared in Figure 2 . Higher mean PV:isoSK-GFR ratios are found in kidneys that show >15% improvement in SK-GFR following revascularization as compared to normal or insignificant RAS kidneys (P < 0.05). Post-revascularization PV: isoSK-GFR are similar in all groups.
Changes in isoSK-GFR of seven contralateral kidneys were analysed (one patient had contralateral RAO) ( Table  7) . Interestingly, only one contralateral kidney (supplied by a normal vessel) had a high PV:isoSK-GFR ratio, and this 0.6 ± 0. showed a 187% improvement of isoSK-GFR following revascularization of its partner kidney (pre: 5.2; post: 14.9 ml/min). No change in parenchymal volume was seen post-revascularization in kidneys showing >15% SK-GFR improvement or in non-improver kidneys (3.6 ± 5.4 versus 1.1 ± 8.9 ml, NS, respectively).
Discussion
As renal functional outcomes vary after percutaneous endovascular revascularization and given these procedures are not without risks, it is important to improve identification of patients with RAS in whom a beneficial change in renal function will accompany revascularization. We have shown that the relationship between volume and GFR in a RAS kidney can potentially help in determining renal functional outcome following revascularization, which is an important finding. The length of a kidney has traditionally been used to aid ARVD diagnosis, as a surrogate to assess viability, and estimate potential for renal recovery with revascularization procedures [10] . However, we and others have shown that GFR is far more closely correlated to parenchymal volume than renal bipolar length [12, 13] . There has been no study that has examined the relationship of renal morphology (in particular parenchymal volume to SK-GFR) and outcome following renal revascularization. Having previously identified a subgroup of significant RAS kidneys showing a disproportionately higher PV to SK-GFR [13] than other RAS kidneys, we speculated whether such changes might be a manifestation of potentially reversible intra-renal changes-'hibernating parenchyma' [9] . We hypothesized that renal functional outcome following revascularization might be determined by the degree of PV:SK-GFR disproportionality. Hence, in a kidney with high-grade RAS, an improvement in renal function post-revascularization should occur if the PV:SK-GFR ratio is significantly greater than that of an identical volume kidney supplied by a normal or insignificant RAS vessel; and following revascularization, these kidneys should assume the PV:GFR characteristics of kidneys with normal vessel or insignificant RAS, which we found to be the case. We found that patients who had high PV:SK-GFR kidneys with significant RAS who were treated conservatively showed signif- icant decline of eGFR at 1 year compared to the eGFR improvement of the revascularized counterparts (statistically significant eGFR difference at 1 year of 8.6 ml/min/1.73 m 2 ). Kidneys with a high PV:SK-GFR ratio are thought to be 'hibernating' kidneys-i.e. the haemodynamic effect of the stenosis is functionally significant, and the renal tissue beyond the RAS is not irreversibly injured and has the capability of regaining function once the blood supply has improved [9] . Hence, in theory, these kidneys are more likely to manifest an improvement in function following percutaneous transluminal renal angioplasty than those kidneys treated with medical therapy alone; the latter are likely to show progressive renal functional decline, and atrophy [11] because of a persistent and uncorrected haemodynamic ischaemic insult. Treated conservatively, patients with significant RAS kidneys exhibiting high PV:SK-GFR were seven times more likely to show GFR deterioration at 1 year. Conversely, with revascularized patients, treatment of a significant RAS kidney with a high PV:SK-GFR ratio were 28 times more likely to show GFR improvement. Proteinuria is known to be an important marker of progression of renal dysfunction and parenchymal damage in ARVD [21, 22] . This was emphasized in the conservative group where proteinuria >0.5 g/day was a major predictor for renal functional decline (OR 37.5, P = 0.006). Radermacher et al. have shown that a urinary protein excretion of ≥1 g/ day was associated with a worse renal functional outcome in RAS following revascularization [23] , and Chrysochou et al. have also very recently shown a similar effect in a multi-centre retrospective study [24] . However, in the current study, which only included a relatively small number of revascularized patients, the presence of proteinuria >0.5 g/day was not statistically associated with this adverse outcome. There have been suggestions that proteinuria may reflect reversible parenchymal injury possibly relating to high intrarenal angiotensin II production and elevated intra-glomerular pressure [9] . This is supported by several case reports that have described the remission of proteinuria following revascularization [25] [26] [27] .
Renal atrophy is known to occur in ARVD and is associated with renal functional decline [11] . Intervention with revascularization has been shown to preserve kidney length [28] , and renal morphological parameters such as bipolar length, parenchymal thickness and kidney mass can improve in kidneys whose function increases after revascularization [29] . Although we did not demonstrate any significant post-revascularization changes in volume, we accept that our study numbers were small.
Most studies have reported global rather than split kidney function which may not be appropriate and may in part explain conflicting results in the literature. This is well illustrated by La Batide-Alanore et al. who showed that no improvement in global GFR was seen following revascularization; however, when split kidney function was analysed, improvement in GFR was observed in the revascularized kidney, but declined in the contralateral kidney [30] . Similarly, we found no improvement in global eGFR following revascularization but improvements were observed when revascularized kidneys were analysed according to baseline PV:SK-GFR ratios and also when split kidney function was evaluated.
Notwithstanding the findings of La Batide-Alanore et al. [30] , it was interesting to find a great improvement in isoSK-GFR in one contralateral kidney supplied by a 'normal' vessel following revascularization of its counterpart. This finding could be explained by neurohormonal changes. In unilateral RAS, the stenotic kidney increases the secretion of renin and angiotensin II, whereas the contralateral 'normal' kidney manifests reduced secretion but increased circulatory extraction of angiotensin II [31] . Furthermore, early studies showed that the increased rate Fig. 2 . PV:isoSK-GFR characteristics in improvers (>15% improvement in isoSK-GFR) and non-improvers as compared to normal vessel or insignificant RAS group, *P < 0.05. of renin release from an ischaemic kidney led to an increase in renal vascular resistance in the contralateral kidney, these intra-renal vascular changes being reversible by intra-arterial administration of an angiotensin II antagonist [32] . Hence, RAS correction with reduction in renin and angiotensin II secretion might possibly explain the improved GFR observed in the contralateral kidney in our study. This important finding does merit further investigation. A major question that needs to be addressed is why some kidneys should manifest improved renal function whilst others fail to do so after restoring renal artery patency. GFR is closely linked to renal plasma flow; the improver kidneys in our study had a disproportionately low GFR per given parenchymal volume, and hence presumed low renal plasma flow. We would speculate that these kidneys had not already undergone irreversible ischaemic damage (i.e. extensive nephron atrophy and loss, interstitial fibrosis with consequent renal shrinkage) prior to being revascularized; and that the reduced GFR was the result of a hydraulic effect of the RAS. This absence of irreversible damage and potential for improvement of renal function is the rationale for use of the term 'hibernating parenchyma'. We would suggest that those kidneys manifesting no renal functional improvement after revascularization do so either because irreversible parenchymal damage has already occurred due to a haemodynamically significant RAS, or because the RAS lesion is incidental and not haemodynamically significant. One of the major limitations of our study is the small number of revascularized patients who had kidneys with high PV:SK-GFR. The literature has cited that improvements in global GFR following renal revascularization is generally seen in about a fifth of patients, and our findings were comparable with this. However, the use of global estimated GFR from prediction equations rather than measured radioisotopic SK-GFR might well underestimate the improvement in renal function of individual kidneys. We found that, of the 12 revascularized patients with baseline and post-revascularization measurement of radioisotopic global GFR and split function, five patients showed an improvement of global radioisotopic GFR ranging from 18.6% to 178%; and seven of 16 revascularized kidneys showed SK-GFR improvements post-revascularization. The use of measured radioisotopic global GFR and split function over prediction equations is important for accurate assessment of GFR. This is illustrated by one of our patients who had bilateral revascularization; one kidney had a high PV:SK-GFR which exhibited an improvement in SK-GFR from 1.3 to 5 ml/min, whereas the contralateral revascularized kidney had a low or normal PV:SK-GFR which subsequently showed a decline in SK-GFR from 31.2 to 22 ml/min.
For this study, 34 kidneys without evidence of significant RAS provided PV:SK-GFR characteristics for comparison. We acknowledge that the number is small, but nevertheless, in this study, we have shown evidence that it is the relative disproportionality of PV to GFR rather than the absolute size of a given RAS kidney that in part determines the renal functional response post-revascularization. Indeed, in this study, a 'small' kidney of 7.9 cm bipolar length and volume of only 59 ml had a clinically significant >15% functional improvement as a result of revascularization.
We used both 1.0T and 3.0T MR systems to assess renal morphology in this study, and this was entirely because of the way patients were recruited for investigation during the evolution of our research protocol (i.e. 3T scanner became available later in the study). Regardless of the MR system used, we have found the described relationships between PV:SK-GFR and renal functional outcome. Given current issues associating gadolinium with the development of nephrogenic systemic fibrosis in patients with significant renal dysfunction [33] , it is important to note that gadolinium was not required in our MR protocol for volume assessment alone.
In conclusion, our data suggests that in a high-grade RAS kidney, an improvement in renal function post-revascularization should occur if there is a disproportionately high parenchymal volume to SK-GFR. A larger scale study is now required to validate our methods and the usefulness of PV:SK-GFR (or perhaps, cortical volume:SK-GFR) as a predictor of functional outcome following revascularization. Nevertheless, our findings have major implications in managing patients with ARVD, and also improve our understanding of the natural history of atherosclerotic RAS.
